

# Molly McCloskey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4903196/publications.pdf>

Version: 2024-02-01

7  
papers

201  
citations

1478505

6  
h-index

1720034

7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

284  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a murine vertical transmission model for <i>Toxoplasma gondii</i> oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2334-2341.	3.0	52
2	Screening of the Pathogen Box for inhibitors with dual efficacy against <i>Giardia lamblia</i> and <i>Cryptosporidium parvum</i> . <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006673.	3.0	37
3	Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned. <i>International Journal for Parasitology</i> , 2020, 50, 413-422.	3.1	37
4	Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. <i>International Journal for Parasitology</i> , 2017, 47, 753-763.	3.1	30
5	Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3135-3146.	6.4	27
6	Repurposing Infectious Disease Hits as Anti- <i>Cryptosporidium</i> Leads. <i>ACS Infectious Diseases</i> , 2021, 7, 1275-1282.	3.8	8
7	7H-Pyrrolo[2,3-d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1H-Pyrazolo[3,4-d]pyrimidin-4-amine-Based Inhibitors. <i>ACS Infectious Diseases</i> , 2018, 4, 516-522.	3.8	5